Jiangsu, China

Kan Lin

This inventor holds 1 USPTO granted patent. Top assignees: Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kan Lin. Retrieved from https://idiyas.com/inventor/kan-lin-kcbioatu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kan Lin - Innovator in Medical Biotechnology

Introduction

Kan Lin is a prominent inventor based in Jiangsu, China. He has made significant contributions to the field of medical biotechnology, particularly through his innovative research and development efforts.

Latest Patents

Kan Lin holds a patent for the "PVRIG Binding Protein And Its Medical Uses." This invention showcases his expertise in the medical field and highlights his commitment to advancing healthcare solutions.

Career Highlights

Throughout his career, Kan Lin has worked with notable companies such as Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Shanghai Shengdi Pharmaceutical Co., Ltd. His experience in these organizations has allowed him to develop and refine his skills in pharmaceutical research and development.

Collaborations

Kan Lin has collaborated with talented individuals in his field, including Yuan Lin and Xinsheng Jin. These partnerships have contributed to his success and the advancement of his projects.

Conclusion

Kan Lin is a dedicated inventor whose work in medical biotechnology continues to impact the industry positively. His innovative spirit and collaborative efforts are commendable, and his contributions will likely lead to further advancements in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…